FSD Pharma has entered into license agreement with Innovet Italia to develop FDA approved veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats.
FSD Pharma Inc. announced that it has entered into a license agreement with Innovet Italia S.R.L., under which Innovet granted the Company a license to use ultramicronized-palmitoylethanolamide to develop U.S. Food and Drug Administration (FDA) approved veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. In addition, the Company announced the filing of its year-end results and provides corporate updates.
“The licensing agreement with Innovet Italia S.R.I, to evaluate the use of ultra- micro PEA as a veterinary anti-inflammatory prescription drug, is an exciting opportunity for the company to enter into a new and untapped market,” said Dr. Raza Bokhari, Executive Chairman & CEO. “With a balance sheet that is stronger today than it was when we began our journey nearly three years ago, we are actively exploring other M&A and licensing opportunities to expand our drug development pipeline.”
